Key Takeaways
Biologic manufacturing processes frequently evolve during development and commercialization, requiring manufacturers to demonstrate comparability when process changes occur.
Process analytical technology (PAT) enables real-time monitoring of critical process parameters and product attributes, supporting improved process understanding and control.
Advanced analytical tools (e.g., spectroscopy, online chromatography, and model-based monitoring) are expanding PAT capabilities across upstream and downstream biologic manufacturing.
Integrated control strategies that combine PAT with quality-by-design principles can support life cycle management from early development through commercial production.
Although PAT does not replace traditional analytical comparability testing, it strengthens the scientific foundation needed to evaluate manufacturing changes and maintain consistent product quality.
The Role of Process Analytical Technology in Scaling Biologic Manufacturing from Clinical to Commercial
Unlike small molecule drugs, which are typically produced through relatively well-defined chemical synthesis, biologics are complex products manufactured using living systems such as mammalian cells, bacteria, or yeast. These systems are inherently sensitive to their environment, and seemingly small changes in manufacturing conditions can influence product characteristics. As a result, biologic manufacturing requires careful control of both process parameters and product quality attributes across the entire development life cycle.
Scaling manufacturing from early clinical development to commercial production represents one of the most critical transitions in this life cycle. Production processes developed at laboratory or pilot scale must ultimately operate reliably at much larger scales while maintaining consistent product quality. This challenge is particularly significant for biologics because their structure and function can be influenced by numerous process variables, including cell culture conditions, nutrient availability, purification parameters, and processing equipment.
Regulatory frameworks recognize that manufacturing processes will inevitably evolve as products progress through development and commercialization. Guidance from the International Council for Harmonisation (ICH) notes that manufacturers of biologic products frequently introduce changes to their manufacturing processes during development and after approval, including changes related to increased scale.1 In such cases, companies must demonstrate that the product produced after the change remains comparable to that produced previously, ensuring that quality, safety, and efficacy are not adversely affected.
Meeting these expectations requires a deep understanding of how manufacturing processes influence product attributes. Process analytical technology (PAT) has emerged as one of the key frameworks supporting this understanding. By enabling real-time monitoring and improved control of manufacturing processes, PAT provides tools that can strengthen process knowledge, support manufacturing scale-up, and help ensure consistent product quality as biologic manufacturing transitions from clinical to commercial production.
Regulatory Foundations for Comparability and Process Understanding
The regulatory concept of comparability lies at the heart of biologic manufacturing changes. According to ICH guidance, comparability assessments are used to demonstrate that changes to a manufacturing process, including those associated with increased production scale, do not negatively affect product quality, safety, or efficacy.1 These assessments typically integrate multiple sources of evidence, including routine batch analyses, in-process control data, product characterization studies, process validation information, and stability testing results.
Comparability assessments are therefore not based on a single measurement or analytical method but rather on a comprehensive evaluation of how the manufacturing process and product characteristics behave before and after a change. In many cases, demonstrating comparability requires detailed understanding of the critical quality attributes (CQAs) of a product and the process parameters that influence those attributes.
Scientific understanding of quality attributes plays a central role in these evaluations. Studies of biologic comparability emphasize that understanding the relationship between product attributes and clinical performance is essential for assessing whether a manufacturing change has meaningful consequences for product safety or efficacy.2 This emphasis on process knowledge and product characterization reflects a broader shift in regulatory thinking toward science-based manufacturing control strategies.
The U.S. Food and Drug Administration (FDA) introduced the PAT framework to support this shift. The FDA describes PAT as a framework intended to encourage innovative approaches to pharmaceutical development, manufacturing, and quality assurance.3 The goal of PAT is to enable manufacturers to design and control processes through improved measurement and understanding of critical attributes during production.
Importantly, FDA guidance explicitly states that the PAT framework applies to specified biologics over the life cycle of the product.3 This life cycle perspective makes PAT particularly relevant for biologic manufacturing programs that evolve over time as production capacity expands and processes are refined.
Process Understanding as the Basis for Reliable Scale-Up
One of the central ideas underlying the PAT initiative is that manufacturing processes should be designed and controlled based on scientific understanding rather than relying primarily on end-product testing. Improved insight into process behavior can help manufacturers anticipate how changes in operating conditions may influence product quality.
FDA guidance notes that structured development studies — often incorporating experimental design approaches and analytical monitoring tools — can generate insights that support process development, optimization, scale-up, technology transfer, and process control.3 These insights are particularly valuable when manufacturing processes must be transferred between facilities or scaled to larger production volumes.
Research on PAT implementation in biologics manufacturing highlights similar goals. PAT initiatives aim to measure, analyze, monitor, and ultimately control important bioprocess attributes in order to maintain or improve product quality.4 By enabling continuous or near-real-time data collection during manufacturing, PAT tools can help manufacturers understand how process parameters influence product attributes.
This deeper process understanding is especially valuable during the transition from clinical manufacturing to commercial production. Early-stage manufacturing processes are often designed for flexibility and experimentation, whereas commercial manufacturing requires robust and reproducible operations. PAT approaches can help bridge this transition by providing detailed data about how the process behaves under different conditions.
Analytical Technologies Enabling PAT in Biologic Manufacturing
PAT relies on a diverse range of analytical tools capable of monitoring process variables and product attributes during manufacturing. These technologies allow manufacturers to observe the process in real time rather than relying solely on samples analyzed after production is complete.
Spectroscopic techniques have become particularly important in this context. Reviews of spectroscopic monitoring technologies describe how methods, such as Raman spectroscopy and near-infrared spectroscopy, can be used to monitor key aspects of bioprocesses, including cell growth, metabolic activity, product formation, and quality-related parameters.5 These techniques can be implemented directly within manufacturing equipment, enabling in situ monitoring without interrupting production.
Spectroscopic monitoring technologies have gained attention because they can provide noninvasive measurements across a wide range of analytes. Such measurements can generate online process data that help manufacturers monitor critical process parameters and develop improved process control strategies.6
Other analytical technologies are also being developed for PAT applications in biologic manufacturing. For example, research on downstream purification processes has demonstrated the use of online liquid chromatography systems capable of monitoring product attributes in near real time. In one recent study, an online chromatography platform was used to monitor critical product attributes during biotherapeutic purification, enabling rapid analytical cycles and providing insights into process performance.7 The authors suggested that applying PAT principles in biotherapeutic manufacturing could help ensure consistent product quality while also improving productivity and reducing processing time.
These technologies illustrate how PAT tools can generate detailed data about both upstream and downstream processes, helping manufacturers better understand how production conditions influence product characteristics.
Monitoring and Controlling Critical Quality Attributes
A key objective of PAT is to provide insights into the relationship between process parameters and critical quality attributes. CQAs represent the physical, chemical, biological, or microbiological properties that must be controlled to ensure product quality.
Studies of biologic comparability emphasize that scientific understanding of quality attributes and their relationship to product safety and efficacy is essential when evaluating manufacturing changes.2 PAT tools can contribute to this understanding by providing data on how process variables influence product characteristics during manufacturing.
Advanced PAT approaches may integrate real-time analytical measurements with process models and automated control strategies. In such systems, analytical data are combined with computational models that describe the behavior of the manufacturing process. This integration can enable robust operation of both batch and continuous manufacturing systems by allowing manufacturers to adjust operating conditions based on real-time information.4
In addition to direct measurement technologies, model-based monitoring approaches are increasingly being explored. For example, “soft sensors” use mathematical models combined with process data to estimate process variables that may be difficult to measure directly. Soft sensor technology systems can predict process variables and support monitoring and fault detection when direct analytical measurements are not feasible.8 In downstream bioprocessing for biotherapeutic production, soft sensors have been described as a central analytical tool for accessing and maintaining real-time information about critical quality attributes.
By providing continuous data about manufacturing processes, these analytical approaches can help manufacturers better understand the factors that influence product quality.
Scaling Biologic Manufacturing from Clinical to Commercial
The transition from clinical manufacturing to commercial production is one of the most complex phases in biologic development. Manufacturing processes initially developed at laboratory or pilot scale must ultimately operate at much larger volumes while maintaining consistent performance.
Scaling production often requires modifications to equipment, operating parameters, or facility infrastructure. For example, bioreactor volumes may increase dramatically, purification systems may be redesigned to handle larger product loads, and manufacturing processes may be transferred to different facilities. These changes can introduce uncertainty regarding how the process will behave at larger scale.
Efficient development of downstream processes depends on reliable transfer from laboratory experiments to manufacturing-scale operations. Research on downstream bioprocess development highlights the importance of robust approaches for evaluating process changes and assessing their impact on product quality and yield during development and scale-up.9
Equivalence testing strategies may be used to evaluate whether process changes affect product characteristics during process development, optimization, and production. Such strategies align closely with the comparability principles described in regulatory guidance.
PAT technologies can support these efforts by providing additional information about how manufacturing processes behave as scale increases. Real-time monitoring tools can generate data that help manufacturers evaluate process performance during development and technology transfer, enabling more informed decision-making when manufacturing conditions change.
PAT and Integrated Control Strategies for Biologics
As biologic manufacturing processes become more sophisticated, many organizations are adopting integrated control strategies that combine analytical monitoring, process modeling, and risk-based quality management.
Recent research on analytical control strategies for biologics emphasizes that integrated control approaches are essential for successful biologic development and commercialization. Such strategies typically incorporate elements including a target product profile, identification of CQAs, product characterization studies, and analytical methods designed to monitor product quality throughout the manufacturing process.10
These approaches are consistent with quality-by-design (QbD) principles, which emphasize systematic and risk-based strategies for improving process understanding and ensuring reliable manufacturing performance. PAT technologies play an important role in these strategies by providing analytical capabilities that enable manufacturers to monitor and control manufacturing processes more effectively.
Life cycle management is another important element of these control strategies. Modern biologic manufacturing programs often evolve over time as companies refine their processes, expand production capacity, or adopt new technologies. Analytical control strategies must therefore support efficient life cycle management across biologic therapeutic modalities, including the transition from early development through commercial manufacturing.
PAT technologies contribute to this life cycle perspective by enabling continuous process monitoring and data collection across different stages of development and production.
Challenges and Opportunities for PAT Implementation
Despite significant progress in PAT technologies, implementing these systems in biologic manufacturing environments remains challenging. Analytical tools must be robust enough to operate reliably in complex production environments while generating data that can be integrated into manufacturing control systems.
Research on PAT implementation in biopharmaceutical manufacturing has identified several barriers to broader adoption. One challenge is the limited availability of analytical methods capable of meeting the specific requirements of biologic manufacturing processes.7 Analytical tools must often operate in complex biological matrices while providing accurate and reproducible measurements.
Another challenge involves integrating analytical systems with existing manufacturing infrastructure. Real-time monitoring technologies must interface with process control systems and data management platforms to support advanced control strategies.
Despite these challenges, ongoing advances in analytical technologies, data science, and bioprocess modeling are expanding the possibilities for PAT implementation. As manufacturing processes become increasingly data-driven, PAT tools are likely to play an expanding role in enabling real-time monitoring and improved process control.
Toward Knowledge-Driven Biologic Manufacturing
Biologic drug manufacturing requires careful management of process changes across the product life cycle. Regulatory frameworks like ICH Q5E emphasize the importance of demonstrating comparability when manufacturing processes evolve, including during scale-up from clinical to commercial production.
At the same time, regulatory initiatives such as the FDA’s PAT framework encourage manufacturers to develop technologies that improve understanding and control of manufacturing processes. By enabling real-time monitoring and deeper process insight, PAT tools provide valuable information about how manufacturing conditions influence product attributes.
Analytical technologies including spectroscopic sensors, online chromatography systems, and model-based monitoring tools are increasingly being explored to support these goals. These approaches can help manufacturers monitor process variables, understand the relationships between process parameters and product attributes, and develop more robust control strategies.
Although PAT does not replace traditional analytical testing or regulatory comparability assessments, it can strengthen the scientific understanding that underlies those evaluations. As biologic manufacturing continues to evolve, PAT is likely to remain an important component of efforts to ensure consistent product quality while enabling efficient scale-up and commercialization of biologic therapies.
References
1. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process (Q5E). International Council for Harmonisation of Technical Requirement for Registration of Pharmaceuticals for Human Use. 18 Nov. 2004.
2. Ambrogelly, Alexandre, et al. “Analytical Comparability Study of Recombinant Monoclonal Antibody Between US-Licensed and EU-Approved Rituximab.” mAbs. 10: 513–538 (2018).
3. Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance. U.S. Food and Drug Administration. Sep. 2004.
4. Kornecki, Martin and Jochen Strube. “Process Analytical Technology for Advanced Process Control in Biologics Manufacturing with the Aid of Macroscopic Kinetic Modeling.” Bioengineering. 5:25 (2018).
5. Mishra, Abhishek, et al. “Spectroscopic Advances in Real-Time Monitoring of Pharmaceutical Bioprocesses: A Review of Vibrational and Fluorescence Techniques.” Spectroscopy Journal. 3: 12 (2025).
6. Matuszczyk, Jens-Christoph, et al. “Raman Spectroscopy Provides Valuable Process Insights for Cell-Derived and Cellular Products.” Current Opinion in Biotechnology. 81: 102937 (2023).
7. Graf, Tobias, et al. “Expediting Online Liquid Chromatography for Real-Time Monitoring of Product Attributes to Advance Process Analytical Technology in Downstream Processing of Biopharmaceuticals.” Journal of Chromatography A. 1729: 4650013 (2024).
8. Rathore, Anurag Singh, Saxena Nikina, Naveen G Jesubalan. “Digitization in Bioprocessing: The Role of Soft Sensors in Monitoring and Control of Downstream Processing for Production of Biotherapeutic Products.” Biochemical Engineering Journal. 12: 100263 (2022).
9. Yassouridis, Christina, et al. “Strategy to Equivalence Testing for Development and Scale Up of Biopharmaceutical Downstream Processing.” Biochemical Engineering Journal. 235: 116497 (2021).
10. Kendrick, Brent S, et al. “Analytical Control Strategy for Biologics. Part I: Foundations.” Journal of Pharmaceutical Sciences. 114: 103826 (2025).
